financetom
Business
financetom
/
Business
/
Generational Group Capital Markets Advises ClearCourse Consulting in its Sale to HR Path
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Generational Group Capital Markets Advises ClearCourse Consulting in its Sale to HR Path
Oct 3, 2025 1:14 PM

DALLAS--(BUSINESS WIRE)--

Generational Capital Markets (GCM), a member of FINRA/SIPC and a leading mergers and acquisitions consultant for privately held businesses, is pleased to announce the sale of ClearCourse Consulting to HR Path. The acquisition closed June 3, 2025.

Based in Kannapolis, North Carolina, ClearCourse Consulting was founded in 2016 and has earned a strong reputation for delivering impactful Human Capital Management (HCM) system services. The firm specializes in assessments, implementations, and optimization strategies that help organizations fully realize the value of their HCM investments.

Headquartered in Paris, France, HR Path is a global leader in Human Resources solutions with a presence in 28 countries and a team of over 2,500 professionals. Founded in 2001, the company specializes in advisory, implementation, and operational services that help organizations optimize their HR strategies and systems. With a global reach and local expertise, HR Path remains committed to reshaping the future of HR for organizations around the world.

"The addition of ClearCourse Consulting is a strategic step for us. Their well-established expertise in HCM consulting strengthens our pursuit of becoming the global leader in HR transformation," said François Boulet, Co-founder of HR Path.

"Their deep knowledge and strong client relationships in the U.S. complement our global capabilities, enabling us to deliver even more value to our clients. This partnership is not only about growth—it's about synergy, innovation, and a shared commitment to excellence," added Bryant Bateman, Partner at HR Path.

"We're thrilled to begin this new chapter," said Keith Martin, President & CEO of ClearCourse Consulting. "This milestone brings exciting opportunities for our team and reinforces our path toward continued growth and success. We remain committed to delivering exceptional service while embracing new possibilities as part of HR Path."

Generational Capital Market’s President and Supervising Principal, Brenen Hofstadter and his team, led by Senior Managing Director, M&A, Tom Staszak with the support of Vice President, M&A, Aaron Presley, successfully closed the deal. Executive Managing Director, Ed Weber and Senior M&A Advisor, Dave Heymann established the initial relationship with ClearCourse Consulting.

Ryan Binkley, CEO of Generational Group, stated, “This achievement reflects the strength of our team, the clarity of our vision, and the continued trust our clients place in us. We're committed to creating lasting value through every outcome we deliver.”

About Generational Capital Markets, Inc.

Generational Capital Markets, Inc. is a member of FINRA/SIPC. Generational Capital Markets is part of Generational Group, which is headquartered in Dallas, TX, and is a leading, award winning full-service M&A firm. Generational Group has over 300 professionals across 16 offices in North America. The firm empowers business owners to unlock the full value of their companies through a comprehensive suite of services—including strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A consulting, digital solutions, and wealth management.

Celebrating its 20th year, Generational Group has successfully closed over 1,700 transactions and consistently ranks #1 or #2 in all LSEG league tables for deals valued between $25 million and $500 million.

The firm was named 2024 USA Investment Banking Firm of the Year by the Global M&A Network and recognized as Investment Banking Firm of the Year by The M&A Advisor in both 2022 and 2024.

Source: Generational Group Capital Markets

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Aug 12, 2024
09:26 AM EDT, 08/12/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday the US Food and Drug Administration has given rare pediatric disease designation to its drug candidate WVE-N531 to treat boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping. The drug is being assessed in a trial that enrolled 11 boys with the...
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
Aug 12, 2024
Marathon Digital Holdings Inc ( MARA ) shares are trading lower. The company on Monday announced a proposed private offering of convertible senior notes. What Happened: Bitcoin (CRYPTO: BTC) mining company Marathon Digital ( MARA ) said it intends to offer $250 million worth of convertible senior notes due 2031 in a private offering to institutional buyers. The company expects...
EnLink Midstream to Launch Senior Notes Offering
EnLink Midstream to Launch Senior Notes Offering
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- EnLink Midstream ( ENLC ) said Monday that it plans to launch an offering of senior notes. The midstream energy company said it plans to use the net proceeds to repay borrowings under its revolving credit facility, as well as an accounts receivable securitization facility. EnLink said the offering will be fully guaranteed...
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that Anktiva is now available for patients under both commercial and government insurance plans in the US. The US Food and Drug Administration approved Anktiva, the company's immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, in April. Additionally, ImmunityBio ( IBRX ) has started the filing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved